Benzbromarone withdrawn from the European market:  Another case of "absence of evidence is evidence of absence"? [1]

T.L.Th.A. Jansen; M.K. Reinders; E.N. Van Roon; J.R.B.J. Brouwers

Benzbromarone withdrawn from the European market: Another case of "absence of evidence is evidence of absence"? [1]

T.L.Th.A. Jansen, M.K. Reinders, E.N. Van Roon, J.R.B.J. Brouwers

Onderzoeksoutput › Professional

62 Citaten (Scopus)

Originele taal-2	English
Pagina's (van-tot)	651
Aantal pagina's	1
Tijdschrift	Clinical and Experimental Rheumatology
Volume	22
Nummer van het tijdschrift	5
Status	Published - 2004
Extern gepubliceerd	Ja

Handle.net

Permanente koppeling

Citeer dit

@article{746a4a54a84246999b4ea7e93d0eb74e,

title = "Benzbromarone withdrawn from the European market: Another case of {"}absence of evidence is evidence of absence{"}? [1] ",

keywords = "allopurinol, azathioprine, benzbromarone, probenecid, sulfinpyrazone, uric acid, uricosuric agent, drug approval, drug control, drug eruption, drug fatality, drug hypersensitivity, drug indication, drug manufacture, drug marketing, drug safety, drug surveillance program, Europe, face edema, fever, gout, human, letter, liver failure, monotherapy, outcomes research, pathophysiology, prescription, priority journal, tongue disease, uric acid blood level, uric acid urine level",

author = "T.L.Th.A. Jansen and M.K. Reinders and {Van Roon}, E.N. and J.R.B.J. Brouwers",

year = "2004",

language = "English",

volume = "22",

pages = "651",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "CLINICAL & EXPER RHEUMATOLOGY",

number = "5",

}

TY - JOUR

T1 - Benzbromarone withdrawn from the European market

T2 - Another case of "absence of evidence is evidence of absence"? [1]

AU - Jansen, T.L.Th.A.

AU - Reinders, M.K.

AU - Van Roon, E.N.

AU - Brouwers, J.R.B.J.

PY - 2004

Y1 - 2004

KW - allopurinol

KW - azathioprine

KW - benzbromarone

KW - probenecid

KW - sulfinpyrazone

KW - uric acid

KW - uricosuric agent

KW - drug approval

KW - drug control

KW - drug eruption

KW - drug fatality

KW - drug hypersensitivity

KW - drug indication

KW - drug manufacture

KW - drug marketing

KW - drug safety

KW - drug surveillance program

KW - Europe

KW - face edema

KW - fever

KW - gout

KW - human

KW - letter

KW - liver failure

KW - monotherapy

KW - outcomes research

KW - pathophysiology

KW - prescription

KW - priority journal

KW - tongue disease

KW - uric acid blood level

KW - uric acid urine level

M3 - Comment/Letter to the editor

SN - 0392-856X

VL - 22

SP - 651

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 5

ER -